Search Result

Results for "

period

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Angiotensin Receptor (1) Bacterial (1) Biochemical Assay Reagents (2) Calcium Channel (1) Cannabinoid Receptor (1) Casein Kinase (2) CDK (1) Cholecystokinin Receptor (1) Cryptochrome (3) Cytochrome P450 (1) Dopamine Receptor (1) Endogenous Metabolite (5) ERK (1) Herbicide (1) Histone Methyltransferase (1) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (2) mGluR (1) Parasite (2) Potassium Channel (7) SOD (2) Sodium Channel (1) TRP Channel (1) Tyrosinase (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (13) Metabolic Disease (8) Neurological Disease (5)

By Targets:

Akt (1)

Angiotensin Receptor (1)

Bacterial (1)

Biochemical Assay Reagents (2)

Calcium Channel (1)

Cannabinoid Receptor (1)

Casein Kinase (2)

CDK (1)

Cholecystokinin Receptor (1)

Cryptochrome (3)

Cytochrome P450 (1)

Dopamine Receptor (1)

Endogenous Metabolite (5)

ERK (1)

Herbicide (1)

Histone Methyltransferase (1)

HMG-CoA Reductase (HMGCR) (1)

Isotope-Labeled Compounds (2)

mGluR (1)

Parasite (2)

Potassium Channel (7)

SOD (2)

Sodium Channel (1)

TRP Channel (1)

Tyrosinase (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (13)

Metabolic Disease (8)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W010248

2-Phenylglycine DL-α-Phenylglycine	Endogenous Metabolite	Metabolic Disease
2-Phenylglycine (DL-α-Phenylglycine) is a metabolite in breast milk during the W2 to W4 lactation period .

HY-108468

KL001	Cryptochrome	Metabolic Disease
KL001 is a first-in-class cryptochrome (CRY, a flavoproteins that are sensitive to blue light, and is involved in the circadian rhythms of plants and animals) stabilizer which specifically interacts with CRY1 and CRY2. KL001 prevents ubiquitin-dependent degradation of CRY, resulting in lengthening of the circadian period. KL001 has the potential to control fasting hormone-induced gluconeogenesis .

HY-W010248S

2-Phenylglycine-d5 DL-α-Phenylglycine-d₅	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
2-Phenylglycine-d₅ is the deuterium labeled 2-Phenylglycine. 2-Phenylglycine (DL-α-Phenylglycine) is a metabolite in breast milk during the W2 to W4 lactation period[1].

HY-B0910A

Pyrithioxin dihydrochloride Pyritinol dihydrochloride; Pyridoxine disulfide dihydrochloride; Vitamin B6 disulfide dihydrochloride	Endogenous Metabolite	Neurological Disease
Pyrithioxin dihydrochloride is a neurodynamic compound, combined with a short period of hyperventilation (HV) was applied in cerebral infarct patients with Hemiplegia.

HY-W017960

Diludine Et-HE	SOD	Others
Diludine (Et-HE) has antioxidant properties, targeting oxidative stress-related pathways. By improving antioxidative status and reducing β-hydroxybutyrate levels, Diludine alleviates oxidative stress during the parturition period in dairy cows. It is primarily used during the transition period in dairy cows to increase milk yield and milk fat content, as well as to improve health during parturition .

HY-148766

VU661	Others	Metabolic Disease
VU661, a phenazine carboxamide, is a modulator of circadian rhythms to produce a period lengthening of the circadian rhythm. VU661 is a redox-active small molecule .

HY-117627

L 158338	Angiotensin Receptor	Cardiovascular Disease
L 158338 is an angiotensin II receptor antagonist. L 158338 alleviates acidosis and increases coronary blood flow during the ischemic period and increases coronary blood flow during the reperfusion period. L 158338 can be used to study myocardial injury during ischemia and reperfusion .

HY-B0910

Pyrithioxin Pyritinol; Pyridoxine disulfide; Vitamin B6 disulfide	Endogenous Metabolite	Neurological Disease
Pyrithioxin is a neurodynamic compound, combined with a short period of hyperventilation (HV) was applied in cerebral infarct patients with Hemiplegia.

HY-B0615AS

Moricizine-d8(Hydrochloride) EN 313-d₈; Ethmozin-d₈; Moracizine-d₈	Isotope-Labeled Compounds	Cardiovascular Disease
Moricizine-d₈ (Hydrochloride) is the deuterium labeled Moricizine Hydrochloride (HY-B0615A). Moricizine Hydrochloride is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period[1][2].

HY-107036

BMS-394136	Potassium Channel	Cardiovascular Disease
BMS-394136 (compound 1) is a potent inhibitor of Kv 1.5, with an IC₅₀ of 0.05 μM. BMS-394136 is a selective IKur inhibitor. BMS-394136 dose-dependently prolongs atrial effective refractory period (AERP) and action potential duration (APD) without effecting ventricular effective refractory period (VERP). BMS-394136 can be used for acute atrial ischemia research .

HY-113204R

N-Oleoyl glycine (Standard)	Endogenous Metabolite Cannabinoid Receptor Akt	Metabolic Disease
Diludine (Standard) is the analytical standard of Diludine. This product is intended for research and analytical applications. Diludine has antioxidant properties, targeting oxidative stress-related pathways. By improving antioxidative status and reducing β-hydroxybutyrate levels, Diludine alleviates oxidative stress during the parturition period in dairy cows. It is primarily used during the transition period in dairy cows to increase milk yield and milk fat content, as well as to improve health during parturition .

HY-W017960R

Diludine (Standard)	SOD	Others
Diludine (Standard) is the analytical standard of Diludine. This product is intended for research and analytical applications. Diludine has antioxidant properties, targeting oxidative stress-related pathways. By improving antioxidative status and reducing β-hydroxybutyrate levels, Diludine alleviates oxidative stress during the parturition period in dairy cows. It is primarily used during the transition period in dairy cows to increase milk yield and milk fat content, as well as to improve health during parturition .

HY-103232

IEM-1925 bromide	mGluR	Neurological Disease
IEM-1925 bromide is an orally active glutamate receptor antagonist, increases the latent period and decreases the duration of status epilepticus in rats in a lithium-pilocarpine model of epilepsy .

HY-119506

KL044 1 Publications Verification	Cryptochrome	Metabolic Disease
KL044, a stabilizer of the clock protein cryptochrome (CRY) , is a potent chemical probe with a pEC₅₀ value of 7.32, leading to the extension of the circadian period and repression of Per2 activity .

HY-15208A

Clamikalant HMR 1098 free base	Others	Others
Clamikalant (HMR 1098 free base) is a compound used to suppress cardiac arrhythmias. It prevents the reduction of the refractory period during ventricular fibrillation in dogs and also shows antiarrhythmic effects in a rabbit heart model.

HY-N14350

2'''-Hydroxychlorothricin	Bacterial
Hydroxychlorothricin is an antibiotic of the chlorothricin group. Hydroxychlorothricin can be found in Streptomyces sp. K818. Hydroxychlorothricin has anti-tumor effect and can prolong the survival period of ICR mice inoculated with Ehrlich cancer cells .

HY-116478

L-3373	Potassium Channel	Others
L-3373 is a voltage-dependent potassium channel inhibitor with activity that reduces the effective refractory period and the dispersion of monophasic action potential duration, while significantly reducing susceptibility to ventricular fibrillation in a cat model of left ventricular hypertrophy.

HY-134194

KL201 1 Publications Verification	Cryptochrome	Metabolic Disease
KL201 a circadian clock modulator, is a isoform-selective cryptochrome 1 (CRY1) stabilizer. KL201 has no stabilizing effect on CRY2. KL201 lengthens the period of circadian rhythms in cells and tissues .

HY-B0615A

Moricizine Hydrochloride EN 313; Ethmozin; Moracizine	Cytochrome P450	Cardiovascular Disease
Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period .

HY-113896

U-67827E	Cholecystokinin Receptor	Others
U-67827E is a cholecystokinin (CCK) agonist that decreases food intake over a prolonged period of time in baboons. U-67827E may affect the latency to food by inhibiting the movement of food in the stomach and magnifying a gastric distention signal .

HY-130456

AHR 10718	Sodium Channel	Cardiovascular Disease
AHR 10718 is an antiarrhythmic agent that suppresses cardiac arrhythmias induced by digitalis intoxication and myocardial infarction in the intact dog. AHR 10718 also depresses membrane responsiveness and conduction, shortens the effective refractory period of specialized conducting fibers less than action potential duration .

HY-122319

Oxadiargyl RP-020630	Herbicide	Others
Oxadiargyl (RP-020630) is an herbicide that inhibits protoporphyrinogen oxidase and has both pre- and early post-emergent weed activity. Oxadiargyl (RP-020630) has a short residual activity period, broad weed spectrum, and can be used in various soil types .

HY-158976

Sodium lactate ringer's solution Lactated ringer's solution (LRS)	Biochemical Assay Reagents	Others
Sodium lactate ringer's solution is an isotonic crystalloid solution used to regulate body fluids, electrolytes and acid-base balance, and to provide fluid rehydration in the perioperative period. Sodium lactate ringer's solution consists of a sterile aqueous solution of sodium lactate, sodium chloride, potassium chloride, and calcium chloride (RL, 130 mEq sodium/L, 274 mOsm/L) .

HY-17611A1

Etripamil hydrochloride MSP-2017 hydrochloride; (-)-MSP-2017 hydrochloride	Calcium Channel	Neurological Disease
Etripamil (MSP-2017) hydrochloride is a short-acting, L-type calcium channel antagonist that can be used in the study of paroxysmal supraventricular tachycardia (PSVT). Etripamil hydrochloride inhibits calcium influx through slow calcium channels, thereby slowing atrioventricular node conduction and prolonging the atrioventricular node refractory period.

HY-129137

Cyanidin 3-sophoroside chloride Cy 3-soph	Tyrosinase	Others
Cyanidin 3-sophoroside chloride is a potent non-competitive reversible polyphenol oxidase (PPO)/Tyrosinase inhibitor. Also, Cyanidin 3-sophoroside chloride can be used as an anti-browning agent to inhibit the degree of PPO browning, enhance the antioxidant damage capacity of fruits and prolong the storage period .

HY-134338

Ipflufenoquin	Parasite	Others
Ipflufenoquin is an insecticide with the potential to control primary infection with apple scab. Ipflufenoquin should be applied between half an inch of green and fruit set .

HY-134338R

Ipflufenoquin (Standard)	Parasite	Others
(R)-Omeprazole (sodium) (Standard) is the analytical standard of (R)-Omeprazole (sodium). This product is intended for research and analytical applications. (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .

HY-N2333

Resiniferatoxin 1 Publications Verification (+)-Resiniferatoxin	TRP Channel	Cardiovascular Disease Cancer
Resiniferatoxin ((+)-Resiniferatoxin), is a selective agonist of transient receptor potential vanilloid 1 (TRPV1) receptor agonist. Resiniferatoxin can be isolated from the Euphorbia resinifera plant. Resiniferatoxin eliminates TRPV1+ primary sensory afferents and blunt cardiac sympathetic afferent reflex for a relatively long period .

HY-18285

Longdaysin	Casein Kinase ERK CDK	Cancer
Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC₅₀s of 5.6 µM, 8.8 µM, 29 µM, and 52 µM, respectively .

HY-115519

(E/Z)-GO289 2 Publications Verification	Casein Kinase	Cancer
(E/Z)-GO289 is a potent and selective casein kinase 2 (CK2) inhibitor (IC₅₀=7 nM). (E/Z)-GO289 strongly lengthens circadian period. (E/Z)-GO289 exhibits cell type–dependent inhibition of cancer cell growth that correlated with cellular clock function .

HY-14924

Inakalant	Potassium Channel	Cardiovascular Disease
Inakalant is an atrial specific potassium channel blocker with antiarrhythmic activity. Inakalant works by selectively blocking potassium channels in heart cells, thereby prolongs the action potential duration (APD) of cardiomyocytes and increases the effective refractory period of the atria and ventricles, which helps to terminate and prevent the occurrence of arrhythmias such as atrial fibrillation (AF). Inakalant can be used in the study of arrhythmia and cardiac electrophysiology .

HY-118148

UK-66914	Potassium Channel	Cardiovascular Disease
UK-66914, is a class III antiarrhythmic agent that specifically acts on the delayed rectifier potassium current (I_K). UK-66914 is designed to prolong action potential duration (APD) and increase cardiac refractory period, thereby potentially terminating the reentry mechanism in arrhythmias without affecting the serious side effects of antiarrhythmic drugs associated with other ion channels such as Na+ and Ca2+ currents .

HY-120355

AP14145	Potassium Channel	Cardiovascular Disease
AP14145 is an inhibitor for small conductance calcium-activated potassium channel, inhibits K_Ca2.2 channel and K_Ca channel with IC₅₀ of 1.1 μM and 1.1 μM. AP14145 prolongs atrial effective refractory period (AERP) in rats, causes the conversion of atrial fibrillation to sinus rhythum in porcine left ventricular dysfunction models, and exhibits antiarrhythmic effect .

HY-W102545

Diaza-15-crown-5	Biochemical Assay Reagents	Others
Diaza-15-crown-5 extends the lifetime of M intermediates in BR membranes. Diaza-15-crown-5 is a crown ether compound that alters the surface charge of BR membranes. Diaza-15-crown-5 changes the surface charge of the BR film. and overall membrane stability. Diaza-15-crown-5 allows the M state to be maintained for a longer period of time .

HY-120355A

AP14145 hydrochloride	Potassium Channel	Cardiovascular Disease
AP14145 hydrochloride is a potent K_Ca2 (SK) channel negative allosteric modulator with an IC₅₀ of 1.1 μM for K_Ca2.2 (SK2) and K_Ca2.3 (SK3) channels. AP14145 hydrochloride inhibition strongly depends on two amino acids, S508 and A533 in the channel. AP14145 hydrochloride prolonged atrial effective refractory period (AERP) in rats and demonstrates antiarrhythmic effects in a Vernakalant-resistant porcine model of atrial fibrillation (AF) .

HY-19545

SCH-23390 R-(+)-SCH-23390	Dopamine Receptor	Neurological Disease
SCH-23390 is a dopamine D1-like receptor antagonist (with K_i values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively). SCH-23390 can shorten the latency period for cocaine-induced lever pressing behavior in rats. SCH-23390 can also eliminate generalized seizures caused by chemical convulsants, such as arecoline (HY-B0726A) and strychnine, and is used in research on neurological disorders related to the dopamine system .

HY-108998

Bisaramil hydrochloride	Histone Methyltransferase	Cardiovascular Disease
Bisaramil hydrochloride is an antiarrhythmic compound with activity in inhibiting free radical generation. Bisaramil hydrochloride directly blocks sodium currents and exhibits enhanced sodium channel blocking ability. Bisaramil hydrochloride inhibits isoproterenol-induced slow calcium action potentials in cardiomyocytes. Bisaramil hydrochloride reduces heart rate and prolongs the PR, QRS, and QT intervals in the electrocardiogram, showing blocking effects on sodium and potassium channels. Bisaramil hydrochloride reduces cardiac conduction velocity, increases the threshold current for capture and atrial fibrillation, and prolongs the effective refractory period. Bisaramil hydrochloride reduces ventricular arrhythmias and eliminates mortality caused by ventricular fibrillation in ischemic rat hearts .

HY-106281

Bemfivastatin PPD 10558	HMG-CoA Reductase (HMGCR)	Cardiovascular Disease Metabolic Disease
Bemfivastatin (PPD 10558) is an orally active, HMG-CoA Reductase (HMGCR) inhibitor, also known as Statin. Bemfivastatin enhances the activity of liver extraction. Bemfivastatin exhibits little developmental toxicity effects in pregnant rats and rabbits via daily oral doses during organogenesis period. The no observed adverse effect level (NOAEL) are ≥320 mg/kg/day for rats developmental toxicity, 12.5 mg/kg/day for rabbits maternal toxicity, and 25 mg/kg/day for rabbits developmental toxicity, respectively. Bemfivastatin can be used for research on Statin-related hypercholesterolemic myalgia with inability to tolerate statins .

HY-163735

BA6b9	Potassium Channel	Cardiovascular Disease
BA6b9 is an allosteric inhibitor of SK4 channels that targets the CaM–PIP2-binding domain with a IC₅₀ value of 8.6 µM (WT SK4). BA6b9 inhibits SK4 channels by interacting with two specific residues, Arg191 and His192 in the S4–S5 linker. BA6b9 significantly prolongs atrial and atrioventricular effective refractory period (ERP) and reduces atrial fibrillation (AF) induction in rat isolated hearts, which has the potential to be used for the research of arrhythmia .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library	1,144 compounds
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,144 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Coagulation and Anti-coagulation Compound Library

1,144 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,144 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

HY-L040

Anti-diabetic Compound Library	837 compounds
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 837 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Anti-diabetic Compound Library

837 compounds

Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage.

The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes.

MCE Anti-diabetic Compound Library owns a unique collection of 837 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Cat. No.	Product Name	Type